Compare FLNC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNC | EVO |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 778.3M |
| IPO Year | 2021 | 2007 |
| Metric | FLNC | EVO |
|---|---|---|
| Price | $11.30 | $1.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $15.71 | $7.00 |
| AVG Volume (30 Days) | ★ 7.2M | 46.0K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,830,000.00 | N/A |
| Revenue This Year | $51.23 | $1.37 |
| Revenue Next Year | $21.30 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.60 | $1.89 |
| 52 Week High | $33.51 | $4.27 |
| Indicator | FLNC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 40.09 |
| Support Level | N/A | $1.90 |
| Resistance Level | $15.89 | $2.20 |
| Average True Range (ATR) | 0.85 | 0.05 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 6.62 | 17.74 |
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.